An­tibi­ot­ic re­sis­tance start­up gets $33M from Boehringer, No­vo; Equi­l­li­um bags a tri-specf­ic

Cen­tau­ri Ther­a­peu­tics has closed a £24 Mil­lion Se­ries A in­vest­ment round to sup­port the ad­vance­ment of its an­timi­cro­bial re­sis­tance R&D work, us­ing its Al­phamer plat­form.

Boehringer In­gel­heim Ven­ture Fund, Evotec SE, and No­vo Hold­ings RE­PAIR Im­pact Fund all led the round while ex­ist­ing in­vestors An­i­ma­trix Founders LLP, Kent Life Sci­ence and Wren Cap­i­tal al­so con­tributed.

Boehringer’s Jo­hannes Zanzinger, Evotec’s Karen Lack­ey, and No­vo Hold­ings’ Camil­la Petryc­er Hansen will all join the board of di­rec­tors. In a state­ment, Hansen said:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER